Boston Scientific (NYSE: BSX) Completes Patient Enrollment for Stent Trial

Boston Scientific Corporation (NYSE: BSX) recently announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical program. PLATINUM is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum chromium PROMUS ((R)) Element(TM) Everolimus-Eluting Coronary Stent System.

The trial enrolled 1,532 patients with up to two de novo lesions at more than 140 sites worldwide, and completed enrollment two months ahead of schedule. The PLATINUM workhorse trial evaluates the new PROMUS Element Everolimus-Eluting Coronary Stent in comparison with the current PROMUS Stent, which uses the same drug dose and polymer on an earlier cobalt chromium alloy stent design. Two parallel sub-trials will evaluate the PROMUS Element Stent in small vessels and long lesions. In addition to the PROMUS Element Everolimus-Eluting Stent, the Company is developing additional variations of a bare-metal and paclitaxel-eluting stent on the Element platform. The pivotal PERSEUS clinical trial compares the TAXUS ((R)) Element(TM) Stent to the TAXUS Express2(TM) Stent. The PERSEUS trial completed enrollment in October 2008, and the primary endpoint will be reported at the ACC conference in 2010.

"The brisk enrollment in the PLATINUM trial reflects the strong interest in this new platinum chromium stent platform," said Gregg W. Stone, M.D., Professor of Medicine and the Director of Research and Education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital and Principal Investigator of the trial. The Element Stent platform features a proprietary platinum chromium alloy, designed specifically for coronary stents. This alloy, coupled with a new stent architecture, is designed to allow thinner struts, increased flexibility and a lower profile, while improving radial strength, recoil and visibility. In addition, all three Element Stents incorporate the new Apex(TM) Dilatation Catheter technology, designed to enhance deliverability. "We are pleased to bring the next-generation Element drug-eluting stent platform another step closer to commercialization," said Hank Kucheman, Senior Vice President and Group President, Cardiovascular for Boston Scientific. "We are confident that the next-generation Element platform - to be offered in everolimus, paclitaxel and bare-metal versions - will further extend our global drug-eluting stent leadership.” The PROMUS Element, TAXUS Element and bare-metal Element Stents are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

Wall Street Grand is the best investor relations company on the web. From Research Reports to Stock Profiles, we give you everything you need to make the best investment decisions daily. Each of our Featured Investment Opportunities hold premium characteristics to succeed even our own expectations making us the best kept secret of Wall Street.

To feature a company on our web site please contact us at the email listed below.

Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. Please click here to read the full disclaimer.